Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EBT: 2009-2024

Historic EBT for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Dec 2024 value amounting to $216.3 million.

  • Catalyst Pharmaceuticals' EBT rose 24.18% to $71.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $285.8 million, marking a year-over-year increase of 51.38%. This contributed to the annual value of $216.3 million for FY2024, which is 128.82% up from last year.
  • As of FY2024, Catalyst Pharmaceuticals' EBT stood at $216.3 million, which was up 128.82% from $94.5 million recorded in FY2023.
  • In the past 5 years, Catalyst Pharmaceuticals' EBT registered a high of $216.3 million during FY2024, and its lowest value of $41.9 million during FY2020.
  • For the 3-year period, Catalyst Pharmaceuticals' EBT averaged around $138.5 million, with its median value being $104.7 million (2022).
  • Its EBT has fluctuated over the past 5 years, first fell by 9.75% in 2023, then skyrocketed by 128.82% in 2024.
  • Over the past 5 years, Catalyst Pharmaceuticals' EBT (Yearly) stood at $41.9 million in 2020, then rose by 25.73% to $52.7 million in 2021, then spiked by 98.83% to $104.7 million in 2022, then fell by 9.75% to $94.5 million in 2023, then surged by 128.82% to $216.3 million in 2024.